Mechanistic Study on the Species Differences in Excretion Pathway of HR011303 in Humans and Rats

Excretion of [14C]HR011303-derived radioactivity showed significant species difference. Urine (81.50% of dose) was the main excretion route in healthy male subjects, whereas feces (87.16% of dose) was the main excretion route in rats. To further elucidate the underlying cause for excretion species differences of HR011303, studies were conducted to uncover its metabolism and excretion mechanism. M5, a glucuronide metabolite of HR011303, is the main metabolite in humans and rats. Results of a rat microsome incubation study suggested that HR011303 was metabolized to M5 in the rat liver. According to previous studies, M5 is produced in both human liver and kidney microsomes. We found that M5 in the human liver can be transported to the blood by multidrug resistance-associated protein (MRP) 3, and then the majority of M5 can be hydrolyzed to HR011303. HR011303 enters the human kidney or liver through passive diffusion, whereas M5 is taken up through organic anion transporter (OAT) 3, organic anion-transporting polypeptide (OATP) 1B1, and OATP1B3. When HR011303 alone is present, it can be metabolized to M5 in both sandwich-cultured rat hepatocytes (SCRH) and sandwich-cultured human hepatocytes (SCHH) and excreted into bile as M5 in SCRH. Using transporter inhibitors in sandwich-cultured model and membrane vesicles expressing MRP2 or Mrp2, we found that M5 was a substance of MRP2/Mrp2, and the bile efflux of M5 was mainly mediated by MRP2/Mrp2. Considering the significant role of MRP3/Mrp3 and MRP2/Mrp2 in the excretion of glucuronides, the competition between them for M5 was possibly the determinant for the different excretion routes in humans and rats. SIGNIFICANCE STATEMENT Animal experiments are necessary to predict dosage and safety of candidate drugs prior to clinical trials. However, extrapolation results often differ from the actual situation. For HR011303, excretory pathways exhibited a complete reversal, through urine in humans and feces in rats. Such phenomena have been observed in several drugs, but no in-depth studies have been conducted to date. In the present study, the excretion species differences of HR011303 can be explained by the competition for M5 between MRP2/Mrp2 and MRP3/Mrp3.

[1]  T. Hang,et al.  An LC-MS/MS method for quantification of HR011303, a novel highly selective urate transporter 1 inhibitor in beagle dogs and the application to a pharmacokinetic study. , 2019, Biomedical chromatography : BMC.

[2]  Caroline A. Lee,et al.  Metabolism and disposition of lesinurad, a uric acid reabsorption inhibitor, in humans , 2018, Xenobiotica; the fate of foreign compounds in biological systems.

[3]  Xiaoyan Chen,et al.  Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide , 2016, Drug design, development and therapy.

[4]  Sheridan M. Hoy.  Lesinurad: First Global Approval , 2016, Drugs.

[5]  Jiong Lan,et al.  Discovery of potent and orally bioavailable inhibitors of Human Uric Acid Transporter 1 (hURAT1) and binding mode prediction using homology model. , 2016, Bioorganic & medicinal chemistry letters.

[6]  T. Nakanishi,et al.  Local Drug–Drug Interaction of Donepezil with Cilostazol at Breast Cancer Resistance Protein (ABCG2) Increases Drug Accumulation in Heart , 2016, Drug Metabolism and Disposition.

[7]  X. Chu,et al.  Interspecies Variability in Expression of Hepatobiliary Transporters across Human, Dog, Monkey, and Rat as Determined by Quantitative Proteomics , 2015, Drug Metabolism and Disposition.

[8]  Sanjay K. Nigam,et al.  What do drug transporters really do? , 2014, Nature Reviews Drug Discovery.

[9]  S. Zeng,et al.  Interaction of five anthraquinones from rhubarb with human organic anion transporter 1 (SLC22A6) and 3 (SLC22A8) and drug-drug interaction in rats. , 2014, Journal of ethnopharmacology.

[10]  S. Zeng,et al.  Organic cation transporter 1 mediates the uptake of monocrotaline and plays an important role in its hepatotoxicity. , 2013, Toxicology.

[11]  L Zhang,et al.  Emerging Transporters of Clinical Importance: An Update From the International Transporter Consortium , 2013, Clinical pharmacology and therapeutics.

[12]  Fabian Müller,et al.  Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects , 2013, Pharmacological Reviews.

[13]  Ken Grime,et al.  Species Differences in Biliary Clearance and Possible Relevance of Hepatic Uptake and Efflux Transporters Involvement , 2013, Drug Metabolism and Disposition.

[14]  Xiaoyan Chen,et al.  Mechanistic Studies on the Absorption and Disposition of Scutellarin in Humans: Selective OATP2B1-Mediated Hepatic Uptake Is a Likely Key Determinant for Its Unique Pharmacokinetic Characteristics , 2012, Drug Metabolism and Disposition.

[15]  Guoyu Pan,et al.  Assessment of biliary clearance in early drug discovery using sandwich-cultured hepatocyte model. , 2012, Journal of pharmaceutical sciences.

[16]  Xiaomei Zhuang,et al.  [Evaluation of P-glycoprotein mediated in vitro loperamide biliary excretion with sandwich-cultured rat hepatocytes model]. , 2012, Yao xue xue bao = Acta pharmaceutica Sinica.

[17]  J. Lipscomb,et al.  Differences between Human and Rat Intestinal and Hepatic Bisphenol A Glucuronidation and the Influence of Alamethicin on In Vitro Kinetic Measurements , 2010, Drug Metabolism and Disposition.

[18]  Hiroshi Yamazaki,et al.  Blood concentrations of acrylonitrile in humans after oral administration extrapolated from in vivo rat pharmacokinetics, in vitro human metabolism, and physiologically based pharmacokinetic modeling. , 2010, Regulatory toxicology and pharmacology : RTP.

[19]  K. Brouwer,et al.  An In Vitro Assay to Assess Transporter-Based Cholestatic Hepatotoxicity Using Sandwich-Cultured Rat Hepatocytes , 2010, Drug Metabolism and Disposition.

[20]  Marilyn E. Morris,et al.  Prediction of Biliary Excretion in Rats and Humans Using Molecular Weight and Quantitative Structure–Pharmacokinetic Relationships , 2009, The AAPS Journal.

[21]  Claire Strain-Damerell,et al.  Evaluation of Recombinant Cytochrome P450 Enzymes as an in Vitro System for Metabolic Clearance Predictions , 2009, Drug Metabolism and Disposition.

[22]  Y. Lai,et al.  Absolute Difference of Hepatobiliary Transporter Multidrug Resistance-Associated Protein (MRP2/Mrp2) in Liver Tissues and Isolated Hepatocytes from Rat, Dog, Monkey, and Human , 2009, Drug Metabolism and Disposition.

[23]  Meng Li,et al.  Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  J. Beijnen,et al.  Multidrug Resistance Proteins 2 and 3 Provide Alternative Routes for Hepatic Excretion of Morphine-Glucuronides , 2007, Molecular Pharmacology.

[25]  J. Schellens,et al.  Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies Using Mrp2 (Abcc2) Knockout Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.

[26]  G. Rankin,et al.  Human renal organic anion transporters: characteristics and contributions to drug and drug metabolite excretion. , 2006, Pharmacology & therapeutics.

[27]  Thomas J. Raub,et al.  ALTERED HEPATOBILIARY DISPOSITION OF 5 (AND 6)-CARBOXY-2′,7′-DICHLOROFLUORESCEIN IN Abcg2 (Bcrp1) AND Abcc2 (Mrp2) KNOCKOUT MICE , 2006, Drug Metabolism and Disposition.

[28]  Peijin Zhang,et al.  MODULATION OF HEPATIC CANALICULAR OR BASOLATERAL TRANSPORT PROTEINS ALTERS HEPATOBILIARY DISPOSITION OF A MODEL ORGANIC ANION IN THE ISOLATED PERFUSED RAT LIVER , 2005, Drug Metabolism and Disposition.

[29]  Kim L. R. Brouwer,et al.  The Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts , 2004, Pharmaceutical Research.

[30]  I. Mahmood,et al.  Interspecies scaling of biliary excreted drugs. , 2002, Journal of pharmaceutical sciences.

[31]  K. Klette,et al.  LC-mS analysis of human urine specimens for 2-oxo-3-hydroxy LSD: method validation for potential interferants and stability study of 2-oxo-3-hydroxy LSD under various storage conditions. , 2002, Journal of analytical toxicology.

[32]  P. Borst,et al.  Mammalian ABC transporters in health and disease. , 2002, Annual review of biochemistry.

[33]  C. Hop,et al.  Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. , 1998, Journal of pharmaceutical sciences.

[34]  S K Balani,et al.  Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[35]  Y. Kato,et al.  Species differences in absorption, metabolism and excretion of pranoprofen, a 2-arylpropionic acid derivative, in experimental animals. , 1990, Journal of pharmacobio-dynamics.

[36]  M. Humphrey,et al.  Species differences in the metabolism and excretion of fenclofenac. , 1980, Xenobiotica; the fate of foreign compounds in biological systems.

[37]  I. Lauredo,et al.  Excretion of Cefamandole, Cefazolin, and Cephalothin into T-Tube Bile , 1978, Antimicrobial Agents and Chemotherapy.

[38]  H. Pelzer,et al.  Species differences in metabolism and excretion of bromhexine in mice, rats, rabbits, dogs and man. , 1973, European journal of pharmacology.